August 2009, MilleGen announces the publication of a paper entitled "Alternative-splicing-based bicistronic vectors for ratio-controlled protein expression and application to recombinant antibody production" in Nucleic Acids Research (constructs that allow a ratio-controlled expression of proteins of interest in stably transfected cell lines. [PubMed]...
About
MilleGen S. A. established in October 1999 is a french biotech company specialized in discovery and genetic engineering of antibody.
MilleGen won the national research innovation agency (ANVAR) prize for two consecutive years, 1999 and 2000. The initial goal of MilleGen was to use its proprietary MutaGen technology (a Direct Molecular Evolution technology) to establish a protein diversity platform essential for biotechnology and pharmaceutical companies developing novel proteins for use as therapeutic agents, in diagnostics or for industrial or agricultural applications.
Since 2002, MilleGen has focused on antibodies, their engineering and their development as therapeutic and/or diagnostic molecules. This evolution has been supported by advances in the monoclonal antibodies field in terms of their use as therapeutic molecules as well as in the development of new engineering technologies.
In line with this evolution, MilleGen has developed a technological platform dedicated to the identification and development of fully human antibodies destined for therapeutic and diagnostic applications. The tools developed by MilleGen allow an intervention at all stages of antibody development, from the generation of the candidate antibody up to the production of the whole antibody via phases of optimisation by genetic engineering.
Through the technological platform for antibody development, MilleGen strives to be internationally renowned as a major player in the design of therapeutic proteins (new therapeutic targets) and more particularly of human recombinant antibodies on behalf of pharmaceutical and biotech companies, and also in the development of its own molecules... (About MilleGen)
